How To Find A Home Run Stock

Home Run = A stock that doubles or triples in six months to a year.

Subscribe and I will email you “How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It”

Subscribe in the box on the right, or go to the the bottom where it says “Get your free videos here” and register and I will send you a free pdf copy of “How the Shorts Raid Your Stock, Destroy Your  Company, and What to Do About It” ($20 on Amazon.com in hard copy).  Or email me at lux.investor@gmail.com and put free book in headline.

Go for it!



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

How to Find a Home Run Stock

Webinar by John Lux in April 2009 — at the bottom.

This webinar was done in 2009, near the market’s low.



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

CRYO – American CryoStem Corporation — Buy Recommendation

Research Report

American CryoStem Corporation 
(CRYO:OTCQB)
Price per share $0.55 (January 17, 2013)
52 Week Range $0.12 – $1.04

Summary

American CryoStem (CRYO) is a biotech company in the rapidly developing  stem cell and reconstructive tissue transfer markets. Stem cells, while only in the early stage of development, show enormous promise. CRYO has achieved strategic advantages in this field.

Stem cells are the body’s repair kit and therefore have the potential to aid in the treatment of many diseases, some of which are now considered untreatable. Stem cells also have the potential to serve as an anti-aging “fountain of youth” which are found in May tissues in the body. CRYO is focused on stem cells derived from adipose (fat) tissue because of the ease of retrieval and high concentrations.

CRYO is a leader in collecting and storing stem cells and adipose tissue for future use. Stem cell storage allows stem cells to be collected when the patient is young and healthy for use later as the patient ages or becomes unwell. This will be more and more important as a basic service in using stem cells. Tissue storage allows surgeons to incorporate the latest tissue transfer procedures that can be delivered more effectively and economically utilizing stored tissue form a single harvest (liposuction) procedure.

CRYO is developing a portfolio of strategic patents that will buttress CRYO’s strategic position in the stem cell market.

CRYO’s stem cell storage system and patents allow CRYO to develop and implement a wide range of stem cell-based products, services and applications with large profit margins. The latest such product has just been put on Forbes’ list of Top Ten Fashion and Beauty Startups.

 

These capabilities compel us to conclude that CRYO is a buy and strategic long term play on the stem cell industry.   (more…)



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board

MUMBAI, India, Nov. 14, 2012 /PRNewswire/ – Groupe Athena, Inc. (Pink  Sheets: GATA) announced today record revenues of $15,367,544 for the first quarter ending September 30, 2012, which is a 25% increase over the same period in 2011. Net after tax income for the period was $1,307,293 or $.03 per share which included a one time expense of $407,181 related to the purchase of the company’s new facility in India. Trailing twelve month (ttm) earnings remained strong at nearly $.10 per share. The company also has a very healthy cash position and no long term debt.

The Company’s Chairman, D. Purohit stated, “The pharma industry within our region is still very robust and Groupe Athena is extremely well positioned to continue on our current growth track for the foreseeable future. And with the recently reported asset additions which allow us to perform more services in-house, our margins are also increasing significantly.”

In other news the Company has completed their recent transition from GAAP to the International Financial Reporting Standard (IFRS) for all future audited financials. The Company’s annual report for the recent fiscal yearend on June 30, 2012 which was released on August 20, 2012 was audited using IFRS. With the completion of the audit for this fiscal year end on June 30, 2013 the company will seek to qualify for listing on the NASDAQ Bulletin Board quotation system.

To review the complete quarterly report please go to www.otcmarkets.com/stock/GATA/quote and click on “Financials.”

The company reports it is still committed to funding all capital expenditures entirely from internal cash accruals without any shareholder dilution or debt increases.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

PR Newswire (http://s.tt/1tnJ9)



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

GATA up sharply

As I write this, Tuesday, November 13, 2012, GATA is up sharply in the last few weeks from $0.14 to  $0.32, as it continues its growth as we predicted.

By no means would I consider that this stock has reached its peak.

Hold and be happy!

 

 



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

GATA earnings exceed my predictions, up 116%

GATA earnings rose to a record level, over $4.4 million, or 9.4 cents per share.

“Groupe Athena, Inc. (Pink sheets GATA.PK) today announced record revenues of $44,571,386 for the recent fiscal year ended June 30, 2012, an increase of 78% over the previous year. After tax earnings increased 116% to a record $4,417,047 or $0.094 a share.
The Company’s Chairman, D. Purohit stated, “Though we are pleased with these results, we will continue adding more equipment and concentrate on our marketing efforts to increase revenues. As a result of these efforts, we are confident of reporting record revenues in the current fiscal year too. As many critical drug patents expire for large U.S. manufacturers, our client base is bound to increase. This is an exciting time to be part of our dynamic revenue growth and we look forward to increasing our market share in the Indian pharmaceutical industry.”
Though the company added $4,656,442 in assets, it’s cash positionis extremely healthy with cash and short term assets of $ 3,286,141 as againstcurrent liabilities of $ 84,090. The company is proud of the fact that all equipment and other acquisitions have been made entirely from internally generated cash and it is the commitment of management that future additions to the asset base be accomplished without any further dilution or debt increases.The Company has no plans for shareholder dilution over the next 12-18 months. ”

As I write this, the stock is selling at 20 cents per share, or a little over two times earnings for a company with enormous growth and great cash flow.



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

Groupe Athena, Inc. Announces Record Revenues for Third Quarter and Nine Month Financials, Makes Strategic Equipment Purchase and Explores New Revenue Potential

MUMBAI, India, April 11, 2012 /PRNewswire via COMTEX/ — Groupe Athena, Inc. (Pink sheets GATA.PK) announced they have released their financial results for the third quarter which ended March 31, 2012. Total revenue for the period was $10,378,928 which is 140% greater than the same period in 2011. Net income rose to $1,184,000 compared to $731,644.

For the nine months the company also reported record revenue of $34,558,560 compared to $17,893,325. Net income for the first three quarters of the current fiscal year has more than doubled to $3,524,218 or $.075 per fully diluted share.

The company’s cash increased to more than $3.5 million including the special escrow for the anticipated new facility acquisition. They are extremely excited to have been able to maintain this healthy cash position while still adding $3.61 million worth of new equipment in the last 12 months with no shareholder dilution or assumption of debt.

The company reiterates the recent guidance update which stated annualized revenue should increase to exceed $44 million. Earnings are also expected to increase similarly.

Please go to www.otcmarkets.com/stock/GATA/financials to view all recent filings for GATA.

In other news the company announced they have purchased a medical incinerator which is designed to destroy type 4 pathological waste and infectious, contaminated “red bag” surgical dressings, plastic test devices and other hazardous medical waste. The benefits to the company from the purchase of this device are:

a) Fast, complete, efficient waste disposal.b) Heavy duty refractory lined (rated 1550 deg C), cylindrical primary and secondary chamber.c) 250 kg capacity per batch load.d) Integral 300 litre fuel tank.e) Primary chamber temperatures in excess of 1000 deg C and secondary chamber temperatures of above 900 deg C with a 2.0 second gas retention time.

The company expects to be able to substantially reduce the cost of their waste disposal as much as 70% by eliminating the need for outside services and incinerating their waste onsite.

In addition to the cost savings associated with incineration of their own internal waste products, they are studying the market in Western India and are developing plans to start their own incineration plant with 3 to 4 additional incineration machines which would allow the company to incinerate over 2000 pounds of hazardous waste per batch load. The company believes that as more medical product development comes to the region and as the Indian population grows, the opportunity to profit in the medical waste remediation industry is extremely promising. Current EPA estimates of medically generated hazardous waste products are approximately 16 to 20 lbs per patient per day in the U.S. and the market is estimated to be $1 billion annually. The Indian population is 3 times the size of the domestic market and is increasing.

About Groupe Athena, Inc.

Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 16 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company’s web address is www.groupeathena.com

The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the U.S. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

For more information contact:Paul CornellCorporate Shareholder Relations, Inc.pcornell@totalpublicrelations.com

Safe Harbor StatementCertain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions — activities of competitors and the presence of new or additional competition and conditions of equity markets.

SOURCE Groupe Athena, Inc.

 

 

www.prnewswire.com


Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

GATA: very strong results, increases growth estimates — stock still at a low P/E — BUY!

We recommended GATA for the reasons given in this blog earlier.  Six months results recently announced are very ratifying — Revenues up 231% compared with the same period in 2010, net income up 298% compared with a year earlier, and despite the fact that the company spent $2.2 million on equipment, it still has over $700,000 in cash.

Try to find another stock that can grow this fast without selling more stock! A high growth cash cow.

In fact, management is projecting revenues 10% higher than previous growth estimates.

Yet this stock is selling now at $0.39 although it has earnings annualized at $0.10.

Naturally, this is a steal — a company that is growing like mad at a low P/E.

We reiterate our buy recommendation.

Recall that we have an interest in this stock, see the earlier disclosure.

 

 



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

LPS — glad we covered but still looking for the downside

As I recall, we told you to short LPS at something near $20, then we recently recommended covering LPS short at $14 and change and lo and behold, the stock hits $22.

Somewhere in here the bulls will have to taste LPS’ bitter  reality, but let’s hold off for a sweet entry point on selling more.   Let the bulls give us money on a silver platter.

The stock seems to be rejoicing over the recent mortgage settlement, but we don’t see this as a solution for LPS. Watch and wait.

The stock has a huge institutional ownership and the insiders have been steadily liquidating for some time. As a bear, we like this too.

 



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

LPS short — let’s take the money and run

We recommended LPS as a short because of its robo-signing problems about six months ago at $20. It dropped nicely to about $14 then rallied back to $20 and dropped again. From the buying that came in on the drop (the news was some related indictments) there may be support at this level. Even though I think this thing is an open pit, we have a nice profit, let’s lock it up. It is $14 and change now. Like my father said, “You don’t go broke taking profits.”



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share

The Truth About Volatility That Nobody Tells You

Personally, I LOVE volatility.

Volatility creates opportunity.

That is the secret — people are using volatility to scare you.

People who do not like volatility are telling you that they do not know how to trade.

When prices are too high, you sell, when too low you buy, duh.

So you look for when prices shoot up and then hit the wall. The price will trace out for you where the resistance is after a few days or a week or so. Just be patient and watch until the price pattern reveals where the buyers and sellers are.

You can also trade spikes. If the spike goes too far, you act.



Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks
  • Add to favorites
  • LinkedIn
  • Propeller
  • Reddit
  • Slashdot
  • StumbleUpon
  • Suggest to Techmeme via Twitter
  • Tumblr

About John Lux

Former market maker, investment banker, security analyst, author of "How to Find a Home Run Stock," "How the Shorts Raid Your Stock, Destroy Your Company, and What to Do About It," and "How to Pick Hot Reverse Merger Penny Stocks," all available on Amazon.com Contact me at Lux.investor@gmail.com

Share